<DOC>
	<DOC>NCT00722358</DOC>
	<brief_summary>The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection</brief_summary>
	<brief_title>A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Chronically infected with HCV genotype 1 Treatment naive HCV RNA viral load of ≥10*5 IU/mL BMI 18 to 35kg/m² Women of childbearing potential (WOCBP) Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with HCV infection HCV infected subjects who are treatment nonresponder (defined as subject who received at least 12 weeks of SOC and continue to have a detectable HCV RNA level or subjects who did not attain a 2log decline in HCV RNA levels at 12 weeks and stopped treatment HCV infected subjects who are treatment intolerant (defined as subject who are unable to receive at least 12 weeks of SOC due to toxicities associated with interferon and/or ribavirin HIV and/or HBV positive Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>